Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29440777 | 0.98 | NPC1 (0.57) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| Formic Acid SCHEMBL30211928 | 0.94 | NPC1 (0.54) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| Phosphoric Acid SCHEMBL29440774 | 0.94 | NPC1 (0.54) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| Fumaric Acid SCHEMBL29441849 | 0.91 | NPC1 (0.51) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| Phenylmethanesulfonic Acid SCHEMBL29440778 | 0.84 | KIT (0.47) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| SCHEMBL15747655 | 0.84 | NPC1 (0.53) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| SCHEMBL496758 | 0.84 | NPC1 (0.60) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| SCHEMBL23874273 | 0.83 | NPC1 (0.54) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL30887943 | 0.83 | NPC1 (0.45) | NPC1RAB9AEPHB3TGFBR1ADORA2A | |
| SCHEMBL29440780 | 0.83 | NPC1 (0.45) | NPC1RAB9AEPHB3TGFBR1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697485-B | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119384421-A | Certain chemical entities, compositions and methods | 沐尔佳治疗公司 | 2025-01-28 | — | — | CN | claimed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| EP-4003521-B1 | DIFFERENT FORMS OF 6-CHLORO-2-ETHYL-N-(4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)PIPERIDINE-1-YL)BENZYL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE | QURIENT CO LTD (KR) | 2024-05-29 | — | — | EP | claimed |
| EP-4076453-B1 | A PHARMACEUTICAL ORAL DOSAGE FORM OF Q203 | QURIENT CO LTD (KR) | 2024-05-22 | — | — | EP | claimed |
| CN-117751107-A | Organic pyridine-pyrazole compounds and uses thereof | 博善人工智能剑桥有限公司 | 2024-03-22 | — | — | CN | claimed |
| EP-4247368-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | Third Harmonic Bio, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | claimed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| EP-4157447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-04-05 | — | — | EP | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| EP-3259264-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | claimed |
| WO-2022109595-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | THIRD HARMONIC BIO, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114206445-A | Different forms of 6-chloro-2-ethyl-N- (4- (4- (4- (trifluoromethoxy) phenyl) piperidin-1-yl) benzyl) imidazo [1,2-a ] pyridine-3-carboxamide | 奎利恩特有限公司 | 2022-03-18 | — | — | CN | claimed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| WO-2011073269-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| US-20040122044-A1 | Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations | GRUENENTHAL GMBH (DE) | 2004-06-24 | — | — | US | claimed |
| EP-1372644-A2 | USE OF SUBSTITUTED IMIDAZO 1,2-A]-PYRIDINE-3-YL-AMIDE AND IMIDAZO 1,2-A]-PYRIDINE-3-YL-AMINE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-01-02 | — | — | EP | claimed |
| WO-2002080911-A2 | USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMIDE AND IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMINE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Grünenthal GmbH (DE) | 2002-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | NPC1 1208/4885RAB9A 3458/4885EPHB3 1932/4885 |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | NPC1 3762/4885RAB9A 880/4885EPHB3 2006/4885 |
| US-20040122044-A1 | Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations | NOS1, NAT1, NOS3 | NPC1 1843/4885RAB9A 3336/4885EPHB3 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.